A method for producing a lithium sulfamate which includes (1) reacting a compound (1) represented by the following formula (1):

##STR00001##

wherein X is fluorine, chlorine, bromine, or iodine, with a compound (2) represented by the following formula (2):

##STR00002##

wherein R.sup.1 and R.sup.2 are each individually H or a substituent as defined herein, the substituent optionally containing at least one bi- to hexavalent heteroatom in the structure and being a substituent in which at least one hydrogen atom is optionally replaced with a fluorine atom or a C0-C7 functional group, to obtain a compound (3) represented by the following formula (3):

##STR00003##

wherein R.sup.1 and R.sup.2 are defined as above.

A method for producing a lithium sulfamate which includes (1) reacting a compound (1) represented by the following formula (1):

##STR00001##

wherein X is fluorine, chlorine, bromine, or iodine, with a compound (2) represented by the following formula (2):

##STR00002##

wherein R.sup.1 and R.sup.2 are each individually H or a substituent as defined herein, the substituent optionally containing at least one bi- to hexavalent heteroatom in the structure and being a substituent in which at least one hydrogen atom is optionally replaced with a fluorine atom or a C0-C7 functional group, to obtain a compound (3) represented by the following formula (3):

##STR00003##

wherein R.sup.1 and R.sup.2 are defined as above.

A method for producing a lithium sulfamate which includes (1) reacting a compound (1) represented by the following formula (1):

##STR00001##

wherein X is fluorine, chlorine, bromine, or iodine, with a compound (2) represented by the following formula (2):

##STR00002##

wherein R.sup.1 and R.sup.2 are each individually H or a substituent as defined herein, the substituent optionally containing at least one bi- to hexavalent heteroatom in the structure and being a substituent in which at least one hydrogen atom is optionally replaced with a fluorine atom or a C0-C7 functional group, to obtain a compound (3) represented by the following formula (3):

##STR00003##

wherein R.sup.1 and R.sup.2 are defined as above.

Some embodiments of the invention include inventive catalysts (e.g., compounds of Formula (I) or (Ia)). Other embodiments include compositions comprising the inventive catalysts. Some embodiments include methods of using the inventive catalysts (e.g., in hydrofluorination of an organic compound). Further embodiments include methods for making the inventive catalysts. Additional embodiments of the invention are also discussed herein.

Some embodiments of the invention include inventive catalysts (e.g., compounds of Formula (I) or (Ia)). Other embodiments include compositions comprising the inventive catalysts. Some embodiments include methods of using the inventive catalysts (e.g., in hydrofluorination of an organic compound). Further embodiments include methods for making the inventive catalysts. Additional embodiments of the invention are also discussed herein.

Here are described processes for the preparation of sulfamic acid derivatives, for instance, halogenated derivatives and their metallic or organic salts. The present document also describes the sulfamic acid derivatives thus produced and to their uses, for instance, in electrolyte compositions for electrochemical applications.

Here are described processes for the preparation of sulfamic acid derivatives, for instance, halogenated derivatives and their metallic or organic salts. The present document also describes the sulfamic acid derivatives thus produced and to their uses, for instance, in electrolyte compositions for electrochemical applications.

The invention discloses CA-4 antitumour drug, their synthetic methods and applications. The CA-4 antitumour drug are obtained by introducing an alkoxy group or a fluorine-containing alkoxy group at the 4 position of the natural product Combretastatin and modified with a functional chemical group at its 3 position. The CA-4 derivated anti-tumor drugs of the invention have inhibitory ability on two targets related to tubulin and arylsulfatase, and can be used for anti-tumor treatment. t,?

The invention discloses CA-4 antitumour drug, their synthetic methods and applications. The CA-4 antitumour drug are obtained by introducing an alkoxy group or a fluorine-containing alkoxy group at the 4 position of the natural product Combretastatin and modified with a functional chemical group at its 3 position. The CA-4 derivated anti-tumor drugs of the invention have inhibitory ability on two targets related to tubulin and arylsulfatase, and can be used for anti-tumor treatment. t,?

A method for preparing hydrogen bis(fluorosulfonyl)imide including contacting sulfonyl fluoride with hexamethyl disilazane in an organic solvent. The disclosure also provides a method for preparing lithium bis(fluorosulfonyl)imide (LiFSI). The method includes contacting sulfonyl fluoride with hexamethyl disilazane in an organic solvent and yielding hydrogen bis(fluorosulfonyl)imide; and contacting hydrogen bis(fluorosulfonyl)imide with a lithium compound and yielding lithium bis(fluorosulfonyl)imide.